Skip to content
value.today
Cytosorbents Corporation logo

Cytosorbents Corporation

CTSO
$25 Mmarket cap on Aug 1, 2026-51.9% since Jan 2024
Compare
World rank
#23,615
Revenue
$37 M
For year ending December-2025
Net income
$-8 M
-22.1% margin
SEC filing
Employees
—

Cytosorbents Corporation in brief

Cytosorbents Corporation is a listed company in the Medical Devices industry, based in Princeton, New Jersey, USA. It was founded in 1997. Its market value was $25 M on 1 August 2026, which makes it the 23,615th largest listed company in the world and the 4,088th largest in the USA on this site. In the year to December 2025 it had sales of $37 M and a net loss of $8 M. Phillip P. Chan is its chief executive. Its largest business segments by sales in 2025 were Single reportable segment (100%). Its shares trade under the symbol CTSO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cytosorbents Corporation

CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.

CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark approval in 2011) — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.

The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns (Toraymyxin), which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Cytosorbents Corporation timeline

5 events, 1997–2021
  1. 1997
  2. 🏁
    · approximate
    Founded
  3. 2004
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2006
  6. ✎
    Renamed MedaSorb Technologies CORP
    Formerly Gilder Enterprises Inc.
  7. 2010
  8. ✎
    Renamed Cytosorbents Corp
    Formerly MedaSorb Technologies CORP.
  9. 2021
  10. 💰
    Record revenue of $43 million
    FY2021, the highest of the 8 years on record.

Events of Cytosorbents Corporation from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$93 M$186 M$279 M$372 M2020202120222023202420252026

World rank over time

▼ down 3,353 places since 2020
2020-01-01: #17935#17,93520202021-01-01: #13023#13,02320212022-01-07: #20123#20,12320222022-12-25: #24208#24,20820222023-07-30: #19096#19,09620232024-01-05: #24744#24,74420242026-03-08: #10963#10,96320262026-08-01: #21288#21,2882026

Rank in USA: #3,578 (Jan 2020) · #2,846 (Jan 2021) · #4,018 (Jan 2022) · #4,643 (Dec 2022) · #3,773 (Jul 2023) · #4,038 (Jan 2024) · #2,140 (Mar 2026) · #3,905 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.7×
Price / book
4.2×
Free cash flow yield
-50.2%
Net margin (TTM)
-49.0%
Operating margin
-39.8%
Return on equity
-308.8%
Liabilities / assets
86.6%
Net debt
$10M
Revenue growth
+4.1%
R&D / revenue
50.6%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $23M, net income $-17M$23MFY18Fiscal year ending Dec 2019: revenue $25M, net income $-19M$25MFY19Fiscal year ending Dec 2020: revenue $41M, net income $-8M$41MFY20Fiscal year ending Dec 2021: revenue $43M, net income $-25M$43MFY21Fiscal year ending Dec 2022: revenue $35M, net income $-33M$35MFY22Fiscal year ending Dec 2023: revenue $31M, net income $-29M$31MFY23Fiscal year ending Dec 2024: revenue $36M, net income $-21M$36MFY24Fiscal year ending Dec 2025: revenue $37M, net income $-8M$37MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$37M+4.1%$-15M$-8M-22.1%
Dec 2024$36M+14.5%$-16M$-21M-58.2%
Dec 2023$31M-10.4%$-32M$-29M-94.1%
Dec 2022$35M-19.6%$-32M$-33M-94.6%
Dec 2021$43M+5.3%$-23M$-25M-56.9%
Dec 2020$41M+64.3%$-10M$-8M-19.1%
Dec 2019$25M+10.9%$-19M$-19M-77.2%
Dec 2018$23M—$-16M$-17M-76.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-12M$0M$-13M$-0.13—
Dec 2024$-14M$0M$-15M$-0.38—
Dec 2023$-22M$1M$-22M$-0.65—
Dec 2022$-28M$6M$-34M$-0.75—
Dec 2021$-14M$4M$-18M$-0.57—
Dec 2020$-6M$1M$-6M$-0.20—
Dec 2019$-17M$1M$-17M$-0.60—
Dec 2018$-11M$1M$-12M$-0.56—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$37M
Net income, trailing 12 months
$-18M
RevenueNet income
Three months to Sep 2024: revenue $9M, net income $-3M$9MSep ’24Three months to Dec 2024 (from the annual report): revenue $9M, net income $-8M$9MDec ’24Three months to Mar 2025: revenue $9M, net income $-1M$9MMar ’25Three months to Jun 2025: revenue $10M, net income $2M$10MJun ’25Three months to Sep 2025: revenue $9M, net income $-3M$9MSep ’25Three months to Dec 2025 (from the annual report): revenue $9M, net income $-6M$9MDec ’25Three months to Mar 2026: revenue $9M, net income $-5M$9MMar ’26Three months to Jun 2026: revenue $10M, net income $-4M$10MJun ’26

Latest quarter to Jun 2026: revenue $10M (+0.1% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Cytosorbents Corporation with the US Securities and Exchange Commission.

Annual results

Revenue
$37 M
Operating income
$-15 M
Net income
$-8 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$44 M
Total liabilities
$38 M
Total equity
$6 M

As of December-2025

Top 26 institutional investors in Cytosorbents Corporation#

As of Sep 30, 2026
26 institutions held 420,234 shares (about 0.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 0.6%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Cytosorbents Corporation
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC94,223New0.15%$0 MNov 13, 2026
2CM Management, LLC73,825New0.12%$0 MNov 12, 2026
3Neuberger Berman Group LLC58,187New0.09%$0 MNov 13, 2026
4Skylands Capital, LLC39,526New0.06%$0 MOct 21, 2026
5BlackRock, Inc.31,360New0.05%$0 MNov 13, 2026
6Geode Capital Management, LLC30,099New0.05%$0 MNov 6, 2026
7Pathstone Holdings, LLC27,491New0.04%$0 MNov 13, 2026
8Sargent Investment Group, LLC25,788New0.04%$0 MNov 13, 2026
9Vanguard Fiduciary Trust Co15,806New0.03%$0 MNov 13, 2026
10UBS Group AG8,302New0.01%$0 MNov 10, 2026
11Osaic Holdings, Inc.6,420New0.01%$0 MNov 12, 2026
12Morgan Stanley4,202New0.01%$0 MNov 13, 2026
13Tower Research Capital LLC (TRC)1,486New0.00%$0 MNov 16, 2026
14Nuveen, LLC1,462New0.00%$0 MNov 10, 2026
15Vanguard Global Advisers, LLC694New0.00%$0 MNov 13, 2026
16Wells Fargo & Company/mn612New0.00%$0 MNov 16, 2026
17Northwestern Mutual Wealth Management Co558New0.00%$0 MNov 13, 2026
18Rockefeller Capital Management L.P.82New0.00%$0 MNov 13, 2026
19Global Retirement Partners, LLC52New0.00%$0 MNov 10, 2026
20Fifth Third Bancorp26New0.00%$0 MNov 5, 2026
21Jpmorgan Chase & Co19New0.00%$0 MNov 12, 2026
22Farther Finance Advisors, LLC9New0.00%$0 MOct 8, 2026
23Russell Investments Group, Ltd.2New0.00%$0 MNov 6, 2026
24PNC Financial Services Group, Inc.1New0.00%$0 MNov 6, 2026
25Danske Bank A/s1New0.00%$0 MNov 9, 2026
Show all 26: investors 26 to 26
Institutional investors 26 to 26 in Cytosorbents Corporation
#InstitutionShares heldChange (shares)% heldValueFiled
26BNP Paribas Financial Markets1New0.00%$0 MNov 12, 2026

Mutual funds holding Cytosorbents Corporation#

12 funds hold shares worth $1 M (about 5.1% of the company). Since their previous reports 3 added shares and 4 sold, selling $0 M net.
Mutual funds holding Cytosorbents Corporation
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.27 M$0 M2.0%<0.01%no changeJun 30, 2026
🇺🇸 Neuberger Intrinsic Value FundNeuberger Berman Investment Advisers LLC646,511$0 M1.0%0.02%−0.1%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.574,463$0 M0.91%<0.01%+6.3%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC380,268$0 M0.61%<0.01%+28%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC94,319$0 M0.15%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC78,580$0 M0.13%<0.01%+5.0%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC32,102$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.35,641$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.29,596$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC21,766$0 M0.03%<0.01%−4.9%May 31, 2026
🇺🇸 Column Small Cap Select FundTrust for Professional Managers6,741$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 Column Small Cap FundTrust for Professional Managers2,079$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Cytosorbents Corporation#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$269 K
10 purchases, 4 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$269 K
open market only
Insiders on file
16
since
$215 K$0Dec 2023: bought $215 K (8 trades), sold $0 (0 trades)Dec 23Dec 2024: bought $47 K (3 trades), sold $0 (0 trades)DecJun 2026: bought $149 K (3 trades), sold $0 (0 trades)JunSep 2026: bought $120 K (7 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Cytosorbents Corporation: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Phillip P. ChanChief Executive Officer, DirectorBuy+3,774$6.000$23 K100,996Form 4
filed Alan D. SobelDirectorBuy+1,900$6.120$12 K9,287Form 4
filed Alan D. SobelDirectorBuy+500$6.050$3 K9,787Form 4
filed Alan D. SobelDirectorBuy+100$6.010$6019,887Form 4
filed Vincent CapponiPresident and COOBuy+1,800$6.070$11 K40,114Form 4
filed Vincent CapponiPresident and COOBuy+273$5.900$2 K40,387Form 4
filed Phillip P. ChanChief Executive Officer, DirectorBuy+200,000$0.350$70 K1.94 MForm 4
filed Peter J. MarianiChief Financial OfficerBuy+100,000$0.440$44 K638,113Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cytosorbents Corporation#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
134,896
0.2% of shares · 1.11 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-20 reverse split ; 25-for-1 split

Trading halts

  • 2026-10-16 18:22 UTC, code LUDP, resumed 18:27 UTC
  • 2026-10-16 18:12 UTC, code LUDP, resumed 18:17 UTC
  • 2026-10-16 18:06 UTC, code LUDP, resumed 18:11 UTC
  • 2026-10-01 15:26 UTC, code LUDP, resumed 15:36 UTC
  • 2026-09-04 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 261 shares at $4.40
  • : 61 shares at $5.24
  • : 261 shares at $4.85
  • : 601 shares at $5.35
  • : 13,527 shares at $5.32

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cytosorbents Corporation scorecard#

Passes 3 of the 16 checks that could be worked out: strongest in financial health (1 of 4), weakest in growth (1 of 6). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth1 of 6
    • ✓Revenue grew in the newest year4.1%Revenue up 4.1% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years2.2%2.2% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median2.2%2.2% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-0.13 vs -0.38Diluted EPS -0.13 in fiscal 2025 against -0.38 the year before (report's currency).
    • ✗Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$8 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-39.8%-39.8% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-96.4%-96.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-39.8%-39.8% in fiscal 2025 against -90.9% in 2022.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities2.1×Current ratio 2.12 at the end of fiscal 2025.
    • ✗Debt below equity2.8×Debt to equity 2.83 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-9.47Z-score -9.47 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year14.3%Diluted shares up 14.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Cytosorbents Corporation's statements, beside the median of Medical Devices.

Cytosorbents Corporation: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-39.8%-8.2%
Net margin-22.1%-10.4%
Return on equity-96.4%-16.8%
Revenue growth, 3 years a year2.2%10.8%
Revenue growth4.1%10.4%
Debt to equity2.83×0.64×

3of 9on the Piotroski tests of financial strength

  • Net loss of $8 million, the 16th loss-making year in a row.
  • Free cash flow was negative: -$13 million.
  • The share count rose 14.3% in the year.

Cytosorbents Corporation: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cytosorbents Corporation: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue3736r31r3543412523159.5
Cost of revenue1111r9.1r1411117.47.55.54.0
Gross profit2625r22r21323018159.65.6
Research and development——1615168.8127.73.2r4.1r
Selling, general and administrative3634r38r343628222115r12r
Operating expenses4141r54r52554037311917
Operating income−15−16r−32r−32−23−10−19−16−9.8−11
Other non-operating income (expense)6.2−6.0r1.9r−2.4−2.51.4−1.4−2.20.7−0.6r
Income before tax−8.6−22r−30r−34−25−9.0−20−18−9.1−12r
Income tax−0.4−1.7r−0.8−1.1−0.7−1.1−1.1−0.6−0.7−0.3
Net income including minority interests−8.2−21————————
Net income attributable to shareholders−8.2−21r−29r−33−25−7.8−19−17−8.5−12r
Earnings per share, basic-0.13-0.38-0.65r-0.75-0.57-0.20-0.60-0.56-0.32-0.46r
Earnings per share, diluted-0.13-0.38-0.65r-0.75-0.57-0.20-0.60-0.56-0.32-0.46r
Shares, weighted average (basic)62544544433932———
Shares, weighted average (diluted)62544544433932312825
Balance sheet
Cash and cash equivalents6.23.3r142252711222175.2
Short-term investments—————————0
Receivables7.67.3r6.15.74.55.24.53.92.21.4
Inventory5.32.7r3.4r3.54.82.72.10.80.80.8
Other current assets1.63.3r1.82.52.93.22.11.10.40.3
Current assets2122r25r3464822128217.8
Property, plant and equipment7.89.0r10115.22.11.91.71.40.6
Right-of-use (leased) assets1112r1213131.01.11.4——
Other intangible assets3.23.7r3.94.44.74.23.42.61.8—
Non-current assets—————————1.9
Total assets4447r53r6390902734r249.7
Accounts payable2.93.3r3.81.72.81.82.01.51.21.3
Debt due within a year——2.5——01.70.74.00.8
Current liabilities9.79.8r14r9.714109.96.9r7.84.3r
Long-term debt1714r2.55.0—0139.36.04.1
Lease liabilities (non-current)1212r1313130.60.61.1——
Total liabilities3836r29r2827112417r148.4r
Retained earnings−312−304r−283r−254−221−197−189−170−152−144r
Shareholders' equity5.911r23r3563793.417101.3r
Total liabilities and equity4447r53r6390902734r249.7
Shares outstanding63555444r44r4333322925
Cash-flow statement
Depreciation and amortization1.21.3r1.5r0.90.70.70.60.40.20.2
Share-based compensation2.83.8r4.2r3.44.03.51.74.43.32.8
Cash from operating activities−12−14r−22−28−14−5.6−17−11−6.5−6.7
Capital expenditure−0.2−0.3r−0.5−6.1−3.6−0.7−0.7−0.7−1.0−0.1
Intangible assets bought−0.3−0.4r−0.4−0.4−0.6−1.0−0.8−0.8−0.7−0.5
Cash from investing activities−0.4−0.7r−0.9−6.5−4.3−1.7−1.5−1.5−1.71.6
Debt issued2.515—5.0—1.45.00.75.05.0
Debt repaid—−5.0———−160−0.700
Shares issued————2727141010—
Cash from financing activities9.39.3r145.00.7668.217205.1
Exchange-rate effect on cash————−0.00.1−0.0−0.10.1−0.0
Change in cash−2.0−5.9r−8.2−30−1859−105.012−0.1
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Cytosorbents Corporation sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Total product sales(total)$37 M100%

Business segments

  • Single reportable segment$37 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Cytosorbents Corporation operates: 8 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 8 subsidiaries on file.

Cytosorbents Corporation: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters2 offices1 subsidiary—
🇨🇦 Canada1 subsidiary—
🇫🇷 France1 subsidiary—
🇩🇪 Germany1 subsidiary—
🇮🇳 India1 subsidiary—
🇵🇱 Poland1 subsidiary—
🇨🇭 Switzerland1 subsidiary—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Cytosorbents Corporation#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$808 K
Dr. Phillip P. Chan
Other top executives, average
$679 K
the CEO earned 1.2× this
$100 invested is now
$12
Cytosorbents Corporation: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Phillip P. Chan$808 K$723 K$679 K$12
2024Phillip P. Chan$900 K$953 K$896 K$17
2023Phillip P. Chan$1.3 M$730 K$995 K$20

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Cytosorbents Corporation#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Financial statements withdrawnFiling

Delisting notice 3 · Financial statements withdrawn 1 · Acquisition or sale completed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9

Cytosorbents Corporation: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Acquisition or sale completed8-K
Shareholder vote8-K
Results announced8-K
Financial statements withdrawn8-K
Results announced8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Cytosorbents Corporation
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2013$1 MPrivate placement after listingUnder $2 million24debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Cytosorbents Corporation compares in Medical Devices

  • Market cap$25 M · higher than 16% of 142
  • Revenue$37 M · higher than 25% of 155
  • Net margin-49.0% · higher than 23% of 144
  • Revenue growth4.1% · higher than 29% of 104
  • Price / sales0.7× · lower than 93% of 96
  • Price / book4.2× · lower than 35% of 99
  • FCF yield-50.2% · higher than 17% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Cytosorbents Corporation🇺🇸$25 M—-49.0%+4.1%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cytosorbents Corporation? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cytosorbents Corporation's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cytosorbents Corporation? Suggest a correction